Auswahl der wissenschaftlichen Literatur zum Thema „Dopamine type I receptor“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Inhaltsverzeichnis
Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Dopamine type I receptor" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Zeitschriftenartikel zum Thema "Dopamine type I receptor"
Shariati, G. H., G. Ahangari, M. R. Asadi, F. Poyafard und H. R. Ahmadkhaniha. „Dopamine Receptor Gene Expression Changes in Peripheral Blood Mononuclear Cells from Schizophrenic Patients Treated with Haloperidol and Olanzapine“. European Journal of Inflammation 7, Nr. 2 (Mai 2009): 71–76. http://dx.doi.org/10.1177/1721727x0900700203.
Der volle Inhalt der QuelleSarkar, D. K., K. Chaturvedi, S. Oomizu, N. I. Boyadjieva und C. P. Chen. „Dopamine, Dopamine D2 Receptor Short Isoform, Transforming Growth Factor (TGF)-β1, and TGF-β Type II Receptor Interact to Inhibit the Growth of Pituitary Lactotropes“. Endocrinology 146, Nr. 10 (01.10.2005): 4179–88. http://dx.doi.org/10.1210/en.2005-0430.
Der volle Inhalt der QuellePeiser, Christian, Marcello Trevisani, David A. Groneberg, Q. Thai Dinh, Doerthe Lencer, Silvia Amadesi, Barbara Maggiore, Selena Harrison, Pierangelo Geppetti und Axel Fischer. „Dopamine type 2 receptor expression and function in rodent sensory neurons projecting to the airways“. American Journal of Physiology-Lung Cellular and Molecular Physiology 289, Nr. 1 (Juli 2005): L153—L158. http://dx.doi.org/10.1152/ajplung.00222.2004.
Der volle Inhalt der QuelleMyslivecek, Jaromir. „Dopamine and Dopamine-Related Ligands Can Bind Not Only to Dopamine Receptors“. Life 12, Nr. 5 (19.04.2022): 606. http://dx.doi.org/10.3390/life12050606.
Der volle Inhalt der QuelleHelms, My N., Xi-Juan Chen, Semra Ramosevac, Douglas C. Eaton und Lucky Jain. „Dopamine regulation of amiloride-sensitive sodium channels in lung cells“. American Journal of Physiology-Lung Cellular and Molecular Physiology 290, Nr. 4 (April 2006): L710—L722. http://dx.doi.org/10.1152/ajplung.00486.2004.
Der volle Inhalt der QuelleDing, Guoliang, Rob F. Wiegerinck, Ming Shen, Anca Cojoc, Carlo M. Zeidenweber und Mary B. Wagner. „Dopamine increases L-type calcium current more in newborn than adult rabbit cardiomyocytes via D1 and β2 receptors“. American Journal of Physiology-Heart and Circulatory Physiology 294, Nr. 5 (Mai 2008): H2327—H2335. http://dx.doi.org/10.1152/ajpheart.00993.2007.
Der volle Inhalt der QuelleMORA-FERRER, CARLOS, und VOLKER GANGLUFF. „D2-dopamine receptor blockade impairs motion detection in goldfish“. Visual Neuroscience 17, Nr. 2 (März 2000): 177–86. http://dx.doi.org/10.1017/s0952523800171196.
Der volle Inhalt der QuelleHayashida, Yuki, und Andrew T. Ishida. „Dopamine Receptor Activation Can Reduce Voltage-Gated Na+ Current by Modulating Both Entry Into and Recovery From Inactivation“. Journal of Neurophysiology 92, Nr. 5 (November 2004): 3134–41. http://dx.doi.org/10.1152/jn.00526.2004.
Der volle Inhalt der QuellePfeiffer-Linn, C., und E. M. Lasater. „Dopamine modulates in a differential fashion T- and L-type calcium currents in bass retinal horizontal cells.“ Journal of General Physiology 102, Nr. 2 (01.08.1993): 277–94. http://dx.doi.org/10.1085/jgp.102.2.277.
Der volle Inhalt der QuelleMilienne-Petiot, Morgane, Lucianne Groenink, Arpi Minassian und Jared W. Young. „Blockade of dopamine D1-family receptors attenuates the mania-like hyperactive, risk-preferring, and high motivation behavioral profile of mice with low dopamine transporter levels“. Journal of Psychopharmacology 31, Nr. 10 (27.09.2017): 1334–46. http://dx.doi.org/10.1177/0269881117731162.
Der volle Inhalt der QuelleDissertationen zum Thema "Dopamine type I receptor"
Hatcher-Solis, Candice N. „PHARMACOLOGICAL IMPLICATIONS OF ADENOSINE 2A RECEPTOR- DOPAMINE TYPE 2 RECEPTOR HETEROMERIZATION“. VCU Scholars Compass, 2016. http://scholarscompass.vcu.edu/etd/4458.
Der volle Inhalt der QuelleZANINOVICH, OREL ANTHONY. „THE CLONING OF AN INDR-TYPE DOPAMINE RECEPTOR IN MANDUCA SEXTA“. Thesis, The University of Arizona, 2008. http://hdl.handle.net/10150/192256.
Der volle Inhalt der QuelleMann, Miranda Jane. „A neuropsychological investigation of dopamine receptor 4 differences among attention deficit hyperactivity disorder-combined type and control children /“. Digital version accessible at:, 2000. http://wwwlib.umi.com/cr/utexas/main.
Der volle Inhalt der QuelleGorji, Hassan. „Role of adenylyl cyclase type 5 in the regulation of the dopamine D3 receptor phosphorylation“. Thesis, University of Ottawa (Canada), 2006. http://hdl.handle.net/10393/27364.
Der volle Inhalt der QuelleMaier, Annette Louise. „Comparative regional ontogeny of dopamine D₁ receptor binding and mRNA expression in pre- and postnatal rat brain /“. Zürich, 1994. http://e-collection.ethbib.ethz.ch/show?type=diss&nr=10902.
Der volle Inhalt der QuelleEtchepare, Laetitia. „Role of glutamate N-Methyl-D-Aspartate receptor surface trafficking in the firing pattern of midbrain dopaminergic neurons“. Thesis, Bordeaux, 2017. http://www.theses.fr/2017BORD0849/document.
Der volle Inhalt der QuelleMidbrain dopaminergic (DA) neurons play several key functions in the brain such as the processing of salient information but are also associated with the emergence of pathologies including Parkinson’s disease and drug addiction. Because these processes have in common to modify the firing activity of midbrain DA neurons, it is of crucial importance to understand the mechanisms underlying this activity. Among the various ions channels and receptors involved in the generation of the firing activity of midbrain DA neurons, glutamate N-methyl-D-aspartate receptors (NMDAR) and calciumdependent potassium SK channels strongly modulate the firing pattern and functionally interact in several neuronal types including DA neurons. However, the mechanisms by which they regulate the firing pattern are poorly understood. Since the functional coupling between NMDAR and SK channels depends on their relative membrane distribution, we hypothesized that the lateral diffusion of NMDAR, which regulates the surface localization of the receptor, could play a role in the firing pattern of midbrain DA neurons through the modulation of SK channel function. We showed first that membrane NMDAR was highly mobile in cultured DA neurons. Alteration of its surface trafficking by a crosslink with NMDAR antibodies profoundly modified the regularity of the firing pattern of DA neurons in midbrain slices, whereas pharmacological blockade of NMDAR did not affect it. Furthermore, a SK channel blocker, which induces a similar change in the firing regularity in control conditions, was less effective when NMDAR surface trafficking was altered. Taken together, these results demonstrate that NMDAR surface dynamics modulate the firing pattern of midbrain DA neurons by regulating SK channel function
Roberts-Crowley, Mandy L. „Modulation of Cav1.3 L-Type Calcium Channels by Arachidonic Acid and Muscarinic M1 Receptors: A Dissertation“. eScholarship@UMMS, 2007. https://escholarship.umassmed.edu/gsbs_diss/348.
Der volle Inhalt der QuelleLucas, Guillaume. „Etude in vivo des modalités d'intervention de la sérotonine et des récepteurs sérotoninergiques de type 5-HT/2A/2C, 5-HT3 et 5-HT4 dans le contrôle de la transmission dopaminergique nigro-striée et mésoaccumbale chez le rat“. Bordeaux 2, 1999. http://www.theses.fr/1999BOR28692.
Der volle Inhalt der QuelleHegron, Alan. „Implication des récepteurs de la mélatonine dans les troubles neurologiques et le diabète de type 2 et identification de régions clés du récepteur MT1 responsables de sa sélectivité fonctionnelle“. Thesis, Université Paris-Saclay (ComUE), 2018. http://www.theses.fr/2018SACLS555/document.
Der volle Inhalt der QuelleMelatonin is a neurohormone mainly released from the pineal gland in a circadian manner acting through two G protein-coupled receptors (GPCRs) called MT1 and MT2. Melatonin regulates many important physiological functions. Regulation of dopamine (DA) and glucose levels are two of them but how they do this is not clear.Extracellular DA levels are mainly regulated by its transporter (DAT) which mediates DA re-uptake into presynaptic nerve termini to prevent DA receptor hyperactivation in the presynaptic cleft. Consequently, we verified the role of DAT in the regulation of the DA system by melatonin. We showed that MT1 and MT2, by interacting with the immature non-glycosylated form of DAT retain DAT in the endoplasmic reticulum thus regulating DAT cell surface expression and DA reuptake. Consistently, mice with targeted deletion of MT1 and MT2 show markedly enhanced DA uptake in striatal synaptosomes and decreased amphetamine-induced locomotor activity. Collectively, we revealed here a molecular link between the melatonin and DA systems, which is based on the formation of a molecular complex between melatonin receptors and DAT.To better understand the role of melatonin on the regulation of glucose levels, we studied the involvement of genetic variants of MT2 in the development of type 2 diabetes (T2D). Previous studies showed that natural loss-of-function variants of MT2 associate with T2D risk. To determine more precisely the defective properties linked to T2D risk we monitored spontaneous and melatonin-induced activation of different signaling pathways by 40 MT2 variants. We show that defects in melatonin-induced Gαi and Gαz activation and spontaneous βarrestin-2 recruitment are most significantly associated to T2D risk. Experimental results correlated well with those predicted by evolutionary lineage analysis. This work will help to propose personalized treatments for MT2 variant carriers to recover their defective responses.Sequencing of 9393 individuals resulted in the identification of 32 natural MT1 variants. MT1 wild-type and variants were functionally characterized in bioluminescence resonance energy transfer (BRET) assays. We showed that MT1 activates Gαi/o, Gα12 and Gα15 proteins and recruits βarrestin-2. Analyzes of results by non-linear matrix factorization revealed the existence of 5 clusters characterized by different signaling profiles. Computational homology modeling of the 3D model of MT1 helped to determine the impact of each variant on receptor activation and interaction with G proteins and βarrestin-2. Collectively, our data illustrate that natural variants are powerful tools to understand the molecular basis of GPCR function. Overall, this work contributes to our understanding of the function of melatonin receptors and highlights their importance in the regulation of the DA system and glucose homeostasis. Our results will open new, personalized therapeutic options for patient suffering from a defective DA system or T2D
Thirtamara, Rajamani Keerthi Krishnan. „Animal Models of Drug Addiction and Autism Spectrum Disorders“. The Ohio State University, 2013. http://rave.ohiolink.edu/etdc/view?acc_num=osu1386011455.
Der volle Inhalt der QuelleBücher zum Thema "Dopamine type I receptor"
Tupala, Erkki. Dopamine receptors and transporters in type 1 and 2 alcoholism measured with postmortem human whole hemisphere autoradiography. Kuopio: University of Kuopio, 2001.
Den vollen Inhalt der Quelle findenTiberi, Mario. Dopamine receptor technologies. New York, NY: Humana Press, 2015.
Den vollen Inhalt der Quelle findenTiberi, Mario, Hrsg. Dopamine Receptor Technologies. New York, NY: Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4939-2196-6.
Der volle Inhalt der QuelleDonthamsetti, Prashant Chandra. Dissecting Dopamine D2 Receptor Signaling. [New York, N.Y.?]: [publisher not identified], 2015.
Den vollen Inhalt der Quelle findenL, Waddington John, Hrsg. D1:D2 dopamine receptor interactions. London: Academic Press, 1993.
Den vollen Inhalt der Quelle findenBoileau, Isabelle, und Ginetta Collo, Hrsg. Therapeutic Applications of Dopamine D3 Receptor Function. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-23058-5.
Der volle Inhalt der QuelleKnapp, Mark. Development of dopamine receptor expressing adenoviral vectors. Ottawa: National Library of Canada, 1997.
Den vollen Inhalt der Quelle findenR, Demirdamar, und Jenner Peter 1946-, Hrsg. Dopamine receptor subtypes: From basic science to clinical application. Amsterdam: IOS Press, 1998.
Den vollen Inhalt der Quelle findenRay, Avi Andrew. SH3 binding domains in the dopamine D(3) receptor. Ottawa: National Library of Canada, 1999.
Den vollen Inhalt der Quelle findenZawarynski, Paul. Dopamine D2 receptor monomers, dimers and higher order oligomers. Ottawa: National Library of Canada, 1998.
Den vollen Inhalt der Quelle findenBuchteile zum Thema "Dopamine type I receptor"
Turco, Raymond. „Dopamine Receptor“. In Encyclopedia of Animal Cognition and Behavior, 1–5. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-47829-6_1256-1.
Der volle Inhalt der QuelleTurco, Raymond. „Dopamine Receptor“. In Encyclopedia of Animal Cognition and Behavior, 2120–25. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-319-55065-7_1256.
Der volle Inhalt der QuelleFuxe, Kjell, Daniel Marcellino, Diego Guidolin, Amina Woods und Luigi Agnati. „Dopamine Receptor Oligomerization“. In The Dopamine Receptors, 255–80. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-333-6_10.
Der volle Inhalt der QuelleHazelwood, Lisa A., R. Benjamin Free und David R. Sibley. „Dopamine Receptor-Interacting Proteins“. In The Dopamine Receptors, 219–54. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-333-6_9.
Der volle Inhalt der QuelleDeth, Richard C. „The Dopamine D4 Receptor“. In Molecular Origins of Human Attention, 23–36. Boston, MA: Springer US, 2003. http://dx.doi.org/10.1007/978-1-4615-0335-4_4.
Der volle Inhalt der QuelleRichtand, Neil M., Laurel M. Pritchard und Lique M. Coolen. „Dopamine Receptor Alternative Splicing“. In Dopamine and Glutamate in Psychiatric Disorders, 45–61. Totowa, NJ: Humana Press, 2005. http://dx.doi.org/10.1007/978-1-59259-852-6_2.
Der volle Inhalt der QuelleCivelli, Olivier, James Bunzow, Paul Albert, Hubert H. M. Van Tol und David Grandy. „The Dopamine D2 Receptor“. In Molecular Biology of G-Protein-Coupled Receptors, 160–69. Boston, MA: Birkhäuser Boston, 1992. http://dx.doi.org/10.1007/978-1-4684-6772-7_7.
Der volle Inhalt der QuelleCepeda, Carlos, Véronique M. André, Emily L. Jocoy und Michael S. Levine. „Dopamine Receptor Modulation of Glutamatergic Neurotransmission“. In The Dopamine Receptors, 281–302. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-333-6_11.
Der volle Inhalt der QuelleLee, Frankie H. F., und Albert H. C. Wong. „Dopamine Receptor Genetics in Neuropsychiatric Disorders“. In The Dopamine Receptors, 585–632. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-333-6_19.
Der volle Inhalt der QuelleMoreira, Irina S., Lei Shi, Zachary Freyberg, Spencer S. Ericksen, Harel Weinstein und Jonathan A. Javitch. „Structural Basis of Dopamine Receptor Activation“. In The Dopamine Receptors, 47–73. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-333-6_3.
Der volle Inhalt der QuelleKonferenzberichte zum Thema "Dopamine type I receptor"
Kamasak, Mustafa E., Charles A. Bouman, Bradley T. Christian und Evan D. Morris. „Imaging D2-Dopamine Receptor using PET“. In 2007 IEEE 15th Signal Processing and Communications Applications. IEEE, 2007. http://dx.doi.org/10.1109/siu.2007.4298698.
Der volle Inhalt der QuelleMoritz, Amy E., Nora S. Madaras, Kirsten K. Snyder, Noelia M. Boldizsar, Raphael Haider, Julia Drube, Arun K. Ghosh, John JG Tesmer, Carsten Hoffmann und David R. Sibley. „Regulation of Dopamine Receptor Subtypes by G Protein-Coupled Receptor Kinase Isoforms“. In ASPET 2024 Annual Meeting Abstract. American Society for Pharmacology and Experimental Therapeutics, 2024. http://dx.doi.org/10.1124/jpet.159.988010.
Der volle Inhalt der QuelleLiu, X., J. Guan, F. Tao und B. Mao. „Acupuncture Zusanli Regulate COPD Inflammation Through Dopamine D2 Receptor“. In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a4755.
Der volle Inhalt der QuelleHarrison, J. M., I. Nir, M. Rubinstein, M. J. Low, D. K. Grandy und P. M. Iuvone. „Retinal Function in Dopamine D4 Receptor Knockout (D4KO) Mice“. In Vision Science and its Applications. Washington, D.C.: OSA, 2000. http://dx.doi.org/10.1364/vsia.2000.fd2.
Der volle Inhalt der QuelleJavadi, Arman, Nicholas Forsythe, Alaa Refaat, Jessica-Ann Weir, Hajrah Khawaja, David Waugh, Rohinton Tarapore, Joshua E. Allen, Patrick Johnston und Sandra Van Schaeybroeck. „Abstract 3448: Targeting the dopamine receptor 2 inBRAFmutant colorectal cancer“. In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-3448.
Der volle Inhalt der QuelleUysal, Mehmet Atilla, Ulgen Sever und Sacide Pehlivan. „The dopamine receptor D4 VNTR 48bp gene variant in nicotine addiction“. In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.oa1486.
Der volle Inhalt der QuelleRaghuraman, Gayatri, Nanduri R. Prabhakar und Ganesh K. Kumar. „Dopamine D1 Receptor Signaling Mediates Altered GABA Synthesis By Intermittent Hypoxia“. In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a6630.
Der volle Inhalt der QuelleBlake, Keyana, Basant Hens und Anthony J. Baucum. „Investigating the role of spinophilin in mediating Dopamine D2 Receptor Activity“. In ASPET 2024 Annual Meeting Abstract. American Society for Pharmacology and Experimental Therapeutics, 2024. http://dx.doi.org/10.1124/jpet.321.940880.
Der volle Inhalt der QuelleWen, Ruojian, Xiaoqing Chen, Dan Huang, Minjie Chen und Yuwei Liu. „Sleep Deprivation Increased Dopamine D2 Receptor Expression through Downregulation of miR-9“. In 2015 7th International Conference on Information Technology in Medicine and Education (ITME). IEEE, 2015. http://dx.doi.org/10.1109/itme.2015.122.
Der volle Inhalt der QuelleMadaras, Nora S., Michele L. Rankin, R. Benjamin Free, Raphael Haider, Julia Drube, Arun K. Ghosh, John JG Tesmer, Carsten Hoffmann, David R. Sibley und Amy E. Moritz. „Delineation of the G Protein-Coupled Receptor Kinase Phosphorylation Sites Within the D1 Dopamine Receptor and Their Role in Regulating Receptor Function“. In ASPET 2023 Annual Meeting Abstracts. American Society for Pharmacology and Experimental Therapeutics, 2023. http://dx.doi.org/10.1124/jpet.122.154110.
Der volle Inhalt der QuelleBerichte der Organisationen zum Thema "Dopamine type I receptor"
Dr. Jogeshwar Mukherjee. Development of dopamine receptor radiopharmaceuticals for the study of neurological and psychiatric disorders. Office of Scientific and Technical Information (OSTI), Januar 2009. http://dx.doi.org/10.2172/944919.
Der volle Inhalt der QuelleMukherjee, J. Development of dopamine receptor radiopharmaceuticals for the study of neurological and psychiatric disorders. Progress report 1994--1997. Office of Scientific and Technical Information (OSTI), August 1999. http://dx.doi.org/10.2172/764610.
Der volle Inhalt der QuelleReiss, Michael. Type I Receptor Kinase Inhibitors - A Novel Treatment for Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, Juni 2002. http://dx.doi.org/10.21236/ada408030.
Der volle Inhalt der QuelleFagan, Dedra. Type-I Insulin-Like Growth Factor Receptor (IGF1R)-Estrogen Receptor (ER) Crosstalk Contributes to Antiestrogen Therapy Resistance in Breast Cancer Cells. Fort Belvoir, VA: Defense Technical Information Center, Februar 2013. http://dx.doi.org/10.21236/ada575846.
Der volle Inhalt der QuelleReise, Michael. TGF-beta Type I Receptor Kinase Inhibitors - A Novel Treatment for Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, Juni 2003. http://dx.doi.org/10.21236/ada416442.
Der volle Inhalt der QuelleRausch, Matthew. Enhancement of Dendritic Cell-Based Immunotherapy Using a Small Molecule TGF-beta Receptor Type I Kinase Inhibitor. Fort Belvoir, VA: Defense Technical Information Center, Juni 2008. http://dx.doi.org/10.21236/ada487435.
Der volle Inhalt der QuellePlymate, Stephen R. Therapy of Prostate Cancer Using a Human Antibody Targeting the Type 1 Insulin-Like Growth Factor Receptor (IGF-IR). Fort Belvoir, VA: Defense Technical Information Center, September 2009. http://dx.doi.org/10.21236/ada524529.
Der volle Inhalt der QuelleThomas, Tania, S. Shappell, S. Kasper, R. A. Serra und H. L. Moses. The Development and Characterization of a Transgenic Mouse Model Over-Expressing a Truncated TGF(Beta) Type II Receptor in the Prostate. Fort Belvoir, VA: Defense Technical Information Center, Juli 2000. http://dx.doi.org/10.21236/ada390670.
Der volle Inhalt der QuelleZhuo, Chuanjun, Hongjun Tian, Lina Wang, Xiangyang Gao, Li Ding und Ming Liu. Comparative safety of glucagon like peptide‑1 receptor agonists in patients with type 2 diabetes: a network meta-analysis of cardiovascular outcome trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, August 2020. http://dx.doi.org/10.37766/inplasy2020.8.0122.
Der volle Inhalt der QuelleDeo, Salil, David McAllister, Naveed Sattar und Jill Pell. The time-varying cardiovascular benefits of glucagon like peptide-1 agonist (GLP-RA)therapy in patients with type 2 diabetes mellitus: A meta-analysis of multinational randomized trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, Juli 2021. http://dx.doi.org/10.37766/inplasy2021.7.0097.
Der volle Inhalt der Quelle